AMSTERDAM, April 30, 2025 (GLOBE NEWSWIRE) — DEBRICHEM®, the flagship product of DEBx Medical has been awarded the IIWCG Achievement Award 2025 for Innovation in Wound Care at the [...] Read more »
Curium schließt Übernahme von Monrol im Rahmen seines Plans zur erheblichen Ausweitung der Lutetium-177-Kapazitäten und der Präsenz im Bereich der Positronen-Emissions-Tomographie (PET) ab
- Dies positioniert Curium als führenden Hersteller des Isotops Lu–177
- Integration innovativer [...] Read more »
Curium Finaliza a Aquisição da Monrol como Parte do seu Plano para Expandir Significativamente a Capacidade de Lutécio-177 e Pegada PET
- Aquisição posiciona a Curium como principal fabricante do isótopo Lu–177
- Oferece experiência [...] Read more »
Curium finalise l’acquisition de Monrol, axée sur le net renforcement de sa capacité de production de lutécium-177 et de son empreinte PET
- Affirmation de son leadership dans la production de l’isotope lutétium–177
- Renforcement de son expertise [...] Read more »
Curium Completes the Acquisition of Monrol as Part of its Plan to Significantly Expand Lutetium-177 Capacity and PET Footprint
- Positions Curium as leading manufacturer of Lu–177 isotope
- Brings innovative R&D expertise and pipeline to Curium
- Enhances Curium’s SPECT & PET geographical [...] Read more »
DEBx Medical Secures Expanded Investment from TVM Capital Healthcare
DEBx Medical is poised for accelerated growth in chronic wound solutions, bolstered by the second round of investment by TVM Capital Healthcare.
AMSTERDAM and DUBAI, United Arab Emirates, Nov. 13, 2024 [...] Read more »
A DEBx Medical garante investimento expandido da TVM Capital Healthcare
A DEBx Medical está preparada para um crescimento acelerado em soluções para feridas crônicas, com o apoio da segunda rodada de investimento da TVM Capital Healthcare.
AMSTERDÃ e DUBAI, [...] Read more »
DEBx Medical obtient de nouveaux investissements auprès de TVM Capital Healthcare
Grâce au deuxième tour d’investissement de TVM Capital Healthcare, DEBx Medical s’apprête à accélérer sa croissance dans le domaine des solutions de traitement des plaies [...] Read more »
DEBx Medical sichert sich erweiterte Investition von TVM Capital Healthcare
DEBx Medical ist bereit für ein beschleunigtes Wachstum im Bereich der Lösungen für chronische Wunden, gestützt durch die zweite Investitionsrunde von TVM Capital Healthcare.
AMSTERDAM und DUBAI, [...] Read more »
Angelini Pharma Enters Into An Exclusive Option Agreement With Cureverse to License Global Development and Commercialization Rights For A Novel and Innovative Clinical-Stage Brain Health Asset
- The agreement gives Angelini Pharma an option to exclusive licensing rights to develop and commercialize CV–011, a clinical Phase 1 investigational novel compound with broad [...] Read more »